Medigene (MDGEF) Stock Price, News & Analysis

Company Overview

Medigene AG is a Germany-based biotechnology company focused on developing T-cell-based immunotherapies for the treatment of cancer. The company’s work centers on T-cell receptor-engineered T-cell (TCR-T) therapies, which are designed to direct a patient’s immune cells against tumor-associated antigens.

Medigene’s technology portfolio includes platforms for identifying and optimizing T-cell receptors, engineering therapeutic T cells, and improving their persistence and activity in the tumor environment. Its development programs have included MDG1015, an investigational TCR-T therapy targeting the cancer antigen PRAME for potential use in multiple solid and hematologic cancers. Medigene’s therapies remain in development and are not broadly marketed products.

Founded in 1996, Medigene is headquartered in Planegg/Martinsried, Germany, and has operated as an international biotechnology company through research collaborations and partnerships. Its shares trade in Germany, while American depositary interests have also been quoted over the counter in the United States under the symbol MDGEF.

Key Stats

• Today's Range: $0.10 to $0.10
• 50-Day Range: $0.10 to $0.10
• 52-Week Range: $0.10 to $1.30
• Volume: N/A
• Average Volume: 600 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MDGEF
• CIK: N/A
• Web: www.medigene.com
• Phone: (989) 200-0330
• Fax: N/A
• Employees: 76
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A